Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

about

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Item

http://www.wikidata.org/entity/Q49534551

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Personalization of regorafenib ...... n real-life clinical practice.

@en

Personalization of regorafenib ...... n real-life clinical practice.

@nl

type

Item

label

Personalization of regorafenib ...... n real-life clinical practice.

@en

Personalization of regorafenib ...... n real-life clinical practice.

@nl

prefLabel

Personalization of regorafenib ...... n real-life clinical practice.

@en

Personalization of regorafenib ...... n real-life clinical practice.

@nl

P1476

Personalization of regorafenib ...... n real-life clinical practice.

@en

P2093

Antonio Russo

http://www.w3.org/2001/XMLSchema#string

Bruno Vincenzi

http://www.w3.org/2001/XMLSchema#string

Elena Fumagalli

http://www.w3.org/2001/XMLSchema#string

Giovanni Grignani

http://www.w3.org/2001/XMLSchema#string

Giuseppe Badalamenti

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tonini

http://www.w3.org/2001/XMLSchema#string

Guido Biasco

http://www.w3.org/2001/XMLSchema#string

Lidia Gatto

http://www.w3.org/2001/XMLSchema#string

Lorena Incorvaia

http://www.w3.org/2001/XMLSchema#string

Lorenzo D'Ambrosio

http://www.w3.org/2001/XMLSchema#string

P2860

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Gastrointestinal stromal tumors: report of an audit and review of the literature.

P304

731-739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834017742627

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Giovanni Casali

Annalisa Astolfi

Maristella Saponara

P577

2017-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29449894

http://www.w3.org/2001/XMLSchema#string

P932

5808843

http://www.w3.org/2001/XMLSchema#string